Company Overview and News
KUALA LUMPUR (Oct 2): theedgemarkets.com highlighted twelve stocks with momentum at Bursa Malaysia’s afternoon market close today. All stocks displayed negative momentum.
7108 0162 BSMAF 5256 1818
KUALA LUMPUR (Sept 26): AllianceDBS Research said Ideal Jacobs (M) Corp Bhd (Ijacobs) had on Sept 26 crossed over the 34.5 sen hurdle to an intraday high of 35.5 sen before settling at 34.5 sen (up 2.5 sen or 7.81%).
KUALA LUMPUR (Sept 19): The FBM KLCI is expected to trade range bound today and rise higher on some bargain hunting activities in line with the overnight gains at most global markets.
4863 7235 5196 MYTEF 5202 0162 3484
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484
KUALA LUMPUR (Sept 18): Ideal Jacobs (M) Corp Bhd has won an RM71 million contract to build 301 single-storey link houses in Sabah under the 1Malaysia Civil Servants Housing Programme (PP1AM).
0162 BSMAF 1818
KUALA LUMPUR (Sept 5): The FBM KLCI pared some of its loss at the midday break today, but looked poised to extend its lacklustre start in September.
HLFBF APEXF PBLOF 7090 SPMXF 7036 1082 5681 BATS 4162 0162 1295 8311 6033 5199 PNADF SPMXY 3026 3301 1368 HIPEF PNAGF
KUALA LUMPUR (Sept 5): The FBM KLCI remained in the red at mid-morning and was down 0.52%, in line with the weaker regional markets.
HLFBF APEXF 7173 PBLOF 7090 4065 7036 1082 BATS 4162 0162 1295 8311 6033 PNADF 0104 2216 5819 PNAGF 3719
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...